Author: admin

DelveInsight’s “Underactive Bladder Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Underactive Bladder, historical and forecasted epidemiology as well as the Underactive Bladder market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the Underactive Bladder market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Underactive Bladder Market Forecast

Some of the key facts of the Underactive Bladder Market Report:

• The Underactive Bladder market size is anticipated to grow with a significant CAGR during the study period (2020-2034)

• In October 2024, iota Biosciences, Inc., a fully-owned subsidiary of Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, “Astellas”), announced that the U.S. Food and Drug Administration (FDA) has approved its Investigational Device Exemption (IDE) for an Early Feasibility Study (EFS). This study aims to assess the safety and feasibility of a novel implantable device that delivers electrical stimulation to the bladder wall, triggering contractions to aid bladder emptying in individuals with underactive bladder (UAB).

• In 2023, within the EU4 (Germany, France, Italy, Spain) and the United Kingdom, Germany reported the highest diagnosed prevalent cases of underactive bladder (UAB), estimated at around 200,000 cases. This number is projected to rise by 2034.

• In 2023, there were approximately 14 million cases of moderate to severe lower urinary tract symptoms (LUTS) in Japan, with an estimated 180,000 diagnosed prevalent cases of underactive bladder (UAB). These diagnosed UAB cases are expected to decline in the forecast period from 2024 to 2034.

• TAC-302 and other emerging therapies have shown promising initial results in their clinical trials. Efforts to encourage research and development are crucial to overcome current limitations and promote market growth, especially given the limited options in the pipeline.

• Key Underactive Bladder Companies: Taiho Pharmaceutical, Mirae Cell Bio, Astellas Pharma Europe B.V, Taiho Pharmaceutical, and others

• Key Underactive Bladder Therapies: TAC-302, MR-MC-01, ASP8302, TAC-302, and others

• The Underactive Bladder epidemiology based on gender analyzed that males predominantly has the higher number of diagnosed prevalent cases than females

• The Underactive Bladder market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Underactive Bladder pipeline products will significantly revolutionize the Underactive Bladder market dynamics.

Underactive Bladder Overview

Underactive bladder (UAB), also known as detrusor underactivity (DU), is a condition characterized by reduced bladder contraction strength and/or duration, resulting in incomplete bladder emptying or a prolonged time to empty the bladder. This condition can lead to symptoms such as difficulty initiating urination, a weak urinary stream, the need to strain to urinate, incomplete bladder emptying, and urinary retention.

Get a Free sample for the Underactive Bladder Market Report:

https://www.delveinsight.com/report-store/underactive-bladder-market

Underactive Bladder Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Underactive Bladder Epidemiology Segmentation:

The Underactive Bladder market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:

• Prevalent cases of Lower urinary tract symptoms (LUTS) – moderate to severe in the 7MM

• Diagnosed Prevalent cases of Underactive Bladder (UAB) in the 7MM

• Gender-specific Diagnosed Prevalent cases of Underactive Bladder in the 7MM

• Classification-specific Diagnosed Prevalent cases of Underactive Bladder in the 7MM

• Etiology-specific Diagnosed Prevalent cases of Underactive Bladder in the 7MM

Download the report to understand which factors are driving Underactive Bladder epidemiology trends @ Underactive Bladder Epidemiology Forecast

Underactive Bladder Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Underactive Bladder market or expected to get launched during the study period. The analysis covers Underactive Bladder market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Underactive Bladder Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Underactive Bladder Therapies and Key Companies

• TAC-302: Taiho Pharmaceutical

• MR-MC-01: Mirae Cell Bio

• ASP8302: Astellas Pharma Europe B.V

• TAC-302: Taiho Pharmaceutical

Discover more about therapies set to grab major Underactive Bladder market share @ Underactive Bladder Treatment Market

Underactive Bladder Market Strengths

• The existing treatment paradigm consists mainly of off-label drugs. The untapped market for branded drugs presents lucrative avenues for market growth

Underactive Bladder Market Opportunities

• There is room for branded therapeutic modalities with good safety and efficacy data along with progressive clinical trials

Scope of the Underactive Bladder Market Report

• Study Period: 2020–2034

• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

• Key Underactive Bladder Companies: Taiho Pharmaceutical, Mirae Cell Bio, Astellas Pharma Europe B.V, Taiho Pharmaceutical, and others

• Key Underactive Bladder Therapies: TAC-302, MR-MC-01, ASP8302, TAC-302, and others

• Underactive Bladder Therapeutic Assessment: Underactive Bladder current marketed and Underactive Bladder emerging therapies

• Underactive Bladder Market Dynamics: Underactive Bladder market drivers and Underactive Bladder market barriers

• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies

• Underactive Bladder Unmet Needs, KOL’s views, Analyst’s views, Underactive Bladder Market Access and Reimbursement

To know more about Underactive Bladder companies working in the treatment market, visit @ Underactive Bladder Clinical Trials and Therapeutic Assessment

Table of Contents

1. Underactive Bladder Market Report Introduction

2. Executive Summary for Underactive Bladder

3. SWOT analysis of Underactive Bladder

4. Underactive Bladder Patient Share (%) Overview at a Glance

5. Underactive Bladder Market Overview at a Glance

6. Underactive Bladder Disease Background and Overview

7. Underactive Bladder Epidemiology and Patient Population

8. Country-Specific Patient Population of Underactive Bladder

9. Underactive Bladder Current Treatment and Medical Practices

10. Underactive Bladder Unmet Needs

11. Underactive Bladder Emerging Therapies

12. Underactive Bladder Market Outlook

13. Country-Wise Underactive Bladder Market Analysis (2020–2034)

14. Underactive Bladder Market Access and Reimbursement of Therapies

15. Underactive Bladder Market Drivers

16. Underactive Bladder Market Barriers

17. Underactive Bladder Appendix

18. Underactive Bladder Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432, Las Vegas NV
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Underactive Bladder Market to Expand Significantly by 2034, States DelveInsight Report | Taiho Pharmaceutical, Mirae Cell Bio, Astellas Pharma Europe B.V, Taiho Pharma

The Sickle Cell Disease Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

“Sickle Cell Disease Pipeline Insight, 2024“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Sickle Cell Disease Market.

Some of the key takeaways from the Sickle Cell Disease Pipeline Report:

• Companies across the globe are diligently working toward developing novel Sickle Cell Disease treatment therapies with a considerable amount of success over the years.

• Sickle Cell Disease companies working in the treatment market are – BRL Medicine, Oryzon Genomics, GlaxoSmithKline, Agios Pharmaceuticals, Beam Therapeutics Inc., Graphite Bio, Roche, Quercis Pharma, Editas Medicin, Pfizer, Emmaus Medical, Inc, Vertex Pharmaceuticals, CRISPR therapeutics, Bluebird Bio, Pfizer, Novo Nordisk, Agios Pharmaceuticals, Alexion Pharmaceuticals, Takeda, Prolong Pharmaceuticals, Roche, Beam Therapeutics, Editas Medicine, Sangamo Therapeutics, Bellicum Pharmaceuticals, Invenux, EpiDestiny, Hillhurst Biopharmaceuticals, CSL Behring, Fulcrum Therapeutics, Sana Biotechnology, and others, are developing therapies for the Sickle Cell Disease treatment

• Emerging Sickle Cell Disease therapies in the different phases of clinical trials are- RL 101, ORY-300, GSK 4172239D, AG-946, BEAM-101, Nula-cel, RG 6107, Isoquercetin, Renizgamglogene autogedtemcel, Inclacumab, L-glutamine, CASGEVY, CTX001, LentiGlobin BB305, Inclacumab, Etavopivat, Mitapivat, ALXN1820, TAK-755, Sanguinate, Crovalimab, BEAM101, EDIT 301, BIVV003, BPX-501, SCD-101, Nicotinamide, HBI-002, CSL889, FTX-6058, SG418, and others are expected to have a significant impact on the Sickle Cell Disease market in the coming years.

• In December 2024, Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company specializing in precision genetic medicines using base editing, announced updated safety and efficacy data from its BEACON Phase 1/2 clinical trial of BEAM-101 in sickle cell disease (SCD) patients experiencing severe vaso-occlusive crises (VOCs). The findings were highlighted in the press program for the 66th American Society of Hematology (ASH) Annual Meeting.

• In November 2024, BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a commercial-stage biopharmaceutical company focused on oncology and rare diseases, announced that an abstract featuring initial results from a Phase 1 clinical trial of motixafortide—both as monotherapy and in combination with natalizumab—for CD34+ hematopoietic stem cell (HSC) mobilization in gene therapies for sickle cell disease (SCD) has been accepted for oral presentation at the 66th American Society of Hematology (ASH) Annual Meeting & Exposition, scheduled for December 7-10, 2024, in San Diego, California. Conducted in collaboration with Washington University School of Medicine in St. Louis, this proof-of-concept study explores innovative HSC mobilization strategies aimed at enhancing the treatment experience for SCD patients undergoing gene therapy.

Sickle Cell Disease Overview

Sickle cell disease (SCD), also known as sickle cell anemia, is a genetic disorder characterized by abnormal hemoglobin, the protein in red blood cells responsible for carrying oxygen throughout the body. This condition affects the shape of red blood cells, causing them to become rigid and crescent-shaped, resembling a sickle.

Get a Free Sample PDF Report to know more about Sickle Cell Disease Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/sickle-cell-disease-pipeline-insight

Emerging Sickle Cell Disease Drugs Under Different Phases of Clinical Development Include:

• RL 101: BRL Medicine

• ORY-300: 1 Oryzon Genomics

• GSK 4172239D: GlaxoSmithKline

• AG-946: Agios Pharmaceuticals

• BEAM-101: Beam Therapeutics Inc.

• Nula-cel: Graphite Bio

• RG 6107: Roche

• Isoquercetin: Quercis Pharma

• Renizgamglogene autogedtemcel: Editas Medicin

• Inclacumab: Pfizer

• L-glutamine: Emmaus Medical, Inc

• CASGEVY: Vertex Pharmaceuticals

• ESCAPE: Beam Therapeutic

• IHP-102: IHP Therapeutics

• HBI-002: Hillhurst Biopharmaceuticals

• BEAM101: Beam Therapeutics

• EPI01: Novo Nordisk

• VIT-2763: CSL Vifor

• Inclacumab: Pfizer

• L-glutamine: Emmaus Medical

• Oxbryta: Pfizer

• Exagamglogene autotemcel: CRISPR Therapeutics/Vertex Pharmaceuticals

• Mitapivat: Agios Pharmaceuticals

• Canakinumab: Novartis

• ALXN1820: Alexion Pharmaceuticals

• Crovalimab: Chugai Pharmaceutical/Roche

• EDIT 301: Editas Medicine

• BIVV003: Sangamo Therapeutics

• BEAM101: Beam Therapeutics

• Hemopexin: CSL Behring

Sickle Cell Disease Route of Administration

Sickle Cell Disease pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as

• Intranasal

• Intrathecal

• Intravenous

• Oral

• Oral/Intravenous

• Parenteral

• Subcutaneous

• Subcutaneous/Intramuscular

• Transdermal

Sickle Cell Disease Molecule Type

Sickle Cell Disease Products have been categorized under various Molecule types, such as

• Antisense oligonucleotide

• Gene therapy

• Hormones

• Neuropeptides

• Oligonucleotides

• Small Molecule

• Triglyceride

Sickle Cell Disease Pipeline Therapeutics Assessment

• Sickle Cell Disease Assessment by Product Type

• Sickle Cell Disease By Stage and Product Type

• Sickle Cell Disease Assessment by Route of Administration

• Sickle Cell Disease By Stage and Route of Administration

• Sickle Cell Disease Assessment by Molecule Type

• Sickle Cell Disease by Stage and Molecule Type

DelveInsight’s Sickle Cell Disease Report covers around 50+ products under different phases of clinical development like

• Late-stage products (Phase III)

• Mid-stage products (Phase II)

• Early-stage product (Phase I)

• Pre-clinical and Discovery stage candidates

• Discontinued & Inactive candidates

• Route of Administration

Further Sickle Cell Disease product details are provided in the report. Download the Sickle Cell Disease pipeline report to learn more about the emerging Sickle Cell Disease therapies

Some of the key companies in the Sickle Cell Disease Therapeutics Market include:

Key companies developing therapies for Sickle Cell Disease are – Novartis AG, Global Blood Therapeutics Inc., Emmaus Medical Inc., Addmedica, Medunik USA, Bristol Myers Squibb Co., Sanofi SA, Bluebird Biotechnology, Pfizer Inc., Aruvant Sciences Inc., Glycomimetics Inc., Editas Medicine Inc., CRISPR Therapeutic, and others.

Sickle Cell Disease Pipeline Analysis:

The Sickle Cell Disease pipeline report provides insights into

• The report provides detailed insights about companies that are developing therapies for the treatment of Sickle Cell Disease with aggregate therapies developed by each company for the same.

• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Sickle Cell Disease Treatment.

• Sickle Cell Disease key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

• Sickle Cell Disease Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.

• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Sickle Cell Disease market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Sickle Cell Disease drugs and therapies

Sickle Cell Disease Pipeline Market Drivers

• Increasing prevalence of SCD, rising initiatives by various governments and private organizations are some of the important factors that are fueling the Sickle Cell Disease Market.

Sickle Cell Disease Pipeline Market Barriers

• However, clinical heterogeneity of the disease, associated complications of the disease and other factors are creating obstacles in the Sickle Cell Disease Market growth.

Scope of Sickle Cell Disease Pipeline Drug Insight

• Coverage: Global

• Key Sickle Cell Disease Companies: BRL Medicine, Oryzon Genomics, GlaxoSmithKline, Agios Pharmaceuticals, Beam Therapeutics Inc., Graphite Bio, Roche, Quercis Pharma, Editas Medicin, Pfizer, Emmaus Medical, Inc, Vertex Pharmaceuticals, CRISPR therapeutics, Bluebird Bio, Pfizer, Novo Nordisk, Agios Pharmaceuticals, Alexion Pharmaceuticals, Takeda, Prolong Pharmaceuticals, Roche, Beam Therapeutics, Editas Medicine, Sangamo Therapeutics, Bellicum Pharmaceuticals, Invenux, EpiDestiny, Hillhurst Biopharmaceuticals, CSL Behring, Fulcrum Therapeutics, Sana Biotechnology, and others

• Key Sickle Cell Disease Therapies: RL 101, ORY-300, GSK 4172239D, AG-946, BEAM-101, Nula-cel, RG 6107, Isoquercetin, Renizgamglogene autogedtemcel, Inclacumab, L-glutamine, CASGEVY, CTX001, LentiGlobin BB305, Inclacumab, Etavopivat, Mitapivat, ALXN1820, TAK-755, Sanguinate, Crovalimab, BEAM101, EDIT 301, BIVV003, BPX-501, SCD-101, Nicotinamide, HBI-002, CSL889, FTX-6058, SG418, and others

• Sickle Cell Disease Therapeutic Assessment: Sickle Cell Disease current marketed and Sickle Cell Disease emerging therapies

• Sickle Cell Disease Market Dynamics: Sickle Cell Disease market drivers and Sickle Cell Disease market barriers

Request for Sample PDF Report for Sickle Cell Disease Pipeline Assessment and clinical trials

Table of Contents

1. Sickle Cell Disease Report Introduction

2. Sickle Cell Disease Executive Summary

3. Sickle Cell Disease Overview

4. Sickle Cell Disease- Analytical Perspective In-depth Commercial Assessment

5. Sickle Cell Disease Pipeline Therapeutics

6. Sickle Cell Disease Late Stage Products (Phase II/III)

7. Sickle Cell Disease Mid Stage Products (Phase II)

8. Sickle Cell Disease Early Stage Products (Phase I)

9. Sickle Cell Disease Preclinical Stage Products

10. Sickle Cell Disease Therapeutics Assessment

11. Sickle Cell Disease Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Sickle Cell Disease Key Companies

14. Sickle Cell Disease Key Products

15. Sickle Cell Disease Unmet Needs

16 . Sickle Cell Disease Market Drivers and Barriers

17. Sickle Cell Disease Future Perspectives and Conclusion

18. Sickle Cell Disease Analyst Views

19. Appendix

20. About DelveInsight

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432, Las Vegas NV
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Sickle Cell Disease Pipeline Status 2024: Clinical Trials, MOA, ROA by DelveInsight | Sanofi, Novartis AG, Bluebird Biotech, Pfizer Inc., Aruvant Sciences Inc., Glycomimetics, Global Blood Therapeutic

“Systemic Lupus Erythematosus Pipeline Insight, 2024“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Systemic Lupus Erythematosus Market.

The Systemic Lupus Erythematosus Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Some of the key takeaways from the Systemic Lupus Erythematosus Pipeline Report:

• Companies across the globe are diligently working toward developing novel Systemic Lupus Erythematosus treatment therapies with a considerable amount of success over the years.

• Systemic Lupus Erythematosus companies working in the treatment market are Equillium, Biocon Limited, Kangpu Biopharmaceuticals, Boston Pharmaceuticals, Nektar Therapeutics, AbbVie, Horizon Therapeutics, Sanofi, Biogen, Hoffman-La-Roche, and others, are developing therapies for the Systemic Lupus Erythematosus treatment

• Emerging Systemic Lupus Erythematosus therapies in the different phases of clinical trials are- Mosunetuzumab, Itolizumab, KPG 818, BOS161721, NKTR-358, ABBV-599, Daxdilimab (VIB7734), SAR441344, BIIB059, Obinutuzumab, and others are expected to have a significant impact on the Systemic Lupus Erythematosus market in the coming years.

• In October 2024, The FDA has approved Cullinan Therapeutics’ investigational new drug (IND) application for CLN-978, intended to treat systemic lupus erythematosus (SLE).

• In September 2024, Cartesian Therapeutics, Inc. announced that the U.S. Food and Drug Administration (FDA) has awarded Rare Pediatric Disease Designation to Descartes-08 for treating juvenile dermatomyositis (JDM).

• In September 2024, Caribou Biosciences announced that the U.S. Food and Drug Administration (FDA) has granted fast-track designation to its CAR T-cell therapy CB-010 for the treatment of systemic lupus erythematosus (SLE)

• In September 2024, UCB and Biogen announced positive outcomes from their Phase III PHOENYCS GO clinical trial, evaluating dapirolizumab pegol as a treatment for moderate-to-severe systemic lupus erythematosus.

• In August 2024, Conduit Pharmaceuticals announced plans to conduct a Phase IIa clinical trial to assess AZD1656 for treating multiple autoimmune diseases, including systemic lupus erythematosus (SLE).

• In July 2024, The first patient has been treated with Descartes-08 for systemic lupus erythematosus. This therapy was previously used in patients with myasthenia gravis, a chronic autoimmune disorder causing muscle weakness.

• In February 2024, Idorsia Pharmaceuticals has established a significant global research and development partnership with Viatris to advance and commercialize two Phase III assets, selatogrel and cenerimod, worldwide.

Systemic Lupus Erythematosus Overview

Systemic Lupus Erythematosus (SLE) is a chronic autoimmune disease that can affect various parts of the body. In this condition, the immune system mistakenly attacks healthy tissues and organs, leading to inflammation, pain, and damage to different systems within the body.

Get a Free Sample PDF Report to know more about Systemic Lupus Erythematosus Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/systemic-lupus-erythematosus-pipeline-insight

Emerging Systemic Lupus Erythematosus Drugs Under Different Phases of Clinical Development Include:

• Mosunetuzumab: Roche

• Itolizumab: Equillium/ Biocon Limited

• KPG 818: Kangpu Biopharmaceuticals

• BOS161721: Boston Pharmaceuticals S

• NKTR-358: Nektar Therapeutics

• ABBV-599: AbbVie

• Daxdilimab (VIB7734): Horizon Therapeutics

• SAR441344: Sanofi

• BIIB059: Biogen

• Obinutuzumab: Hoffman-La-Roche

Systemic Lupus Erythematosus Route of Administration

Systemic Lupus Erythematosus pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as

• Intra-articular

• Intraocular

• Intrathecal

• Intravenous

• Ophthalmic

• Oral

• Parenteral

• Subcutaneous

• Topical

• Transdermal

Systemic Lupus Erythematosus Molecule Type

Systemic Lupus Erythematosus Products have been categorized under various Molecule types, such as

• Oligonucleotide

• Peptide

• Small molecule

Systemic Lupus Erythematosus Pipeline Therapeutics Assessment

• Systemic Lupus Erythematosus Assessment by Product Type

• Systemic Lupus Erythematosus By Stage and Product Type

• Systemic Lupus Erythematosus Assessment by Route of Administration

• Systemic Lupus Erythematosus By Stage and Route of Administration

• Systemic Lupus Erythematosus Assessment by Molecule Type

• Systemic Lupus Erythematosus by Stage and Molecule Type

DelveInsight’s Systemic Lupus Erythematosus Report covers around 60+ products under different phases of clinical development like

• Late-stage products (Phase III)

• Mid-stage products (Phase II)

• Early-stage product (Phase I)

• Pre-clinical and Discovery stage candidates

• Discontinued & Inactive candidates

• Route of Administration

Further Systemic Lupus Erythematosus product details are provided in the report. Download the Systemic Lupus Erythematosus pipeline report to learn more about the emerging Systemic Lupus Erythematosus therapies

Some of the key companies in the Systemic Lupus Erythematosus Therapeutics Market include:

Key companies developing therapies for Systemic Lupus Erythematosus are – Sanofi SA, Eli Lilly & Company, Viatris Inc., Novartis AG, GlaxoSmithKline, F. Hoffmann-La Roche AG, Pfizer Limited, ImmuPharma PLC, Bristl Myers Squibb Company, AstraZeneca, Merck & Co., Inc., and others.

Systemic Lupus Erythematosus Pipeline Analysis:

The Systemic Lupus Erythematosus pipeline report provides insights into

• The report provides detailed insights about companies that are developing therapies for the treatment of Systemic Lupus Erythematosus with aggregate therapies developed by each company for the same.

• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Systemic Lupus Erythematosus Treatment.

• Systemic Lupus Erythematosus key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

• Systemic Lupus Erythematosus Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.

• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Systemic Lupus Erythematosus market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Systemic Lupus Erythematosus drugs and therapies

Systemic Lupus Erythematosus Pipeline Market Drivers

• Promising Therapeutic Approaches, increasing Awareness of the Disease, recent Advancements in Research and Development are some of the important factors that are fueling the Systemic Lupus Erythematosus Market.

Systemic Lupus Erythematosus Pipeline Market Barriers

• However, obstacles in Systemic Lupus Erythematosus Pipeline, hit and Trial Approach of Researchers, high Annual Cost of Therapies and other factors are creating obstacles in the Systemic Lupus Erythematosus Market growth.

Scope of Systemic Lupus Erythematosus Pipeline Drug Insight

• Coverage: Global

• Key Systemic Lupus Erythematosus Companies: Equillium, Biocon Limited, Kangpu Biopharmaceuticals, Boston Pharmaceuticals, Nektar Therapeutics, AbbVie, Horizon Therapeutics, Sanofi, Biogen, Hoffman-La-Roche, and others

• Key Systemic Lupus Erythematosus Therapies: Mosunetuzumab, Itolizumab, KPG 818, BOS161721, NKTR-358, ABBV-599, Daxdilimab (VIB7734), SAR441344, BIIB059, Obinutuzumab, and others

• Systemic Lupus Erythematosus Therapeutic Assessment: Systemic Lupus Erythematosus current marketed and Systemic Lupus Erythematosus emerging therapies

• Systemic Lupus Erythematosus Market Dynamics: Systemic Lupus Erythematosus market drivers and Systemic Lupus Erythematosus market barriers

Request for Sample PDF Report for Systemic Lupus Erythematosus Pipeline Assessment and clinical trials

Table of Contents

1. Systemic Lupus Erythematosus Report Introduction

2. Systemic Lupus Erythematosus Executive Summary

3. Systemic Lupus Erythematosus Overview

4. Systemic Lupus Erythematosus- Analytical Perspective In-depth Commercial Assessment

5. Systemic Lupus Erythematosus Pipeline Therapeutics

6. Systemic Lupus Erythematosus Late Stage Products (Phase II/III)

7. Systemic Lupus Erythematosus Mid Stage Products (Phase II)

8. Systemic Lupus Erythematosus Early Stage Products (Phase I)

9. Systemic Lupus Erythematosus Preclinical Stage Products

10. Systemic Lupus Erythematosus Therapeutics Assessment

11. Systemic Lupus Erythematosus Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Systemic Lupus Erythematosus Key Companies

14. Systemic Lupus Erythematosus Key Products

15. Systemic Lupus Erythematosus Unmet Needs

16 . Systemic Lupus Erythematosus Market Drivers and Barriers

17. Systemic Lupus Erythematosus Future Perspectives and Conclusion

18. Systemic Lupus Erythematosus Analyst Views

19. Appendix

20. About DelveInsight

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432, Las Vegas NV
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Systemic Lupus Erythematosus Pipeline Report 2024: Clinical Trials Progress and Therapeutic Advancements | Sanofi SA, Eli Lilly & Company, Viatris Inc., Novartis AG, GlaxoSmithKline, Roche